How to Buy Xeris Biopharma Holdings Stock
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings, Inc. , a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.
Xeris Biopharma Holdings stock last closed at $5.61, up 2.19% from the previous day, and has increased 11.53% in one year. It has overperformed other stocks in the Biotechnology industry by 0.39 percentage points. Xeris Biopharma Holdings stock is currently +47.44% from its 52-week low of $3.81, and -44.35% from its 52-week high of $10.08.
There are currently 172.43M XERS shares outstanding. The market cap of XERS is $967.34M. In the past 24 hours, 1.16M XERS shares were traded.
How to Buy Xeris Biopharma Holdings Stock
Wondering how to invest in Xeris Biopharma Holdings stock? Here's how.
- Choose where to buy Xeris Biopharma Holdings stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Xeris Biopharma Holdings stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your payment method and add your info.
- Research Xeris Biopharma Holdings stock: The Xeris Biopharma Holdings ticker symbol is XERS. Is Xeris Biopharma Holdings stock a good investment? Should you buy shares of XERS? How do XERS's underlying business fundamentals look? Do top analysts think Xeris Biopharma Holdings is a good buy? Why has XERS's stock price moved recently? (Hint: Our stock research tools can help you understand if XERS is a good stock to buy).
- Place your XERS trade: Decide if you will purchase XERS shares at the current market price or use a limit order to purchase XERS stock at a given price.
- Get notifications regarding your XERS investment: Create a watchlist to watch your investment in Xeris Biopharma Holdings stock.
Step 1: Choose where to buy Xeris Biopharma Holdings stock
You need a brokerage account to access the NASDAQ market and buy XERS stock.
Our preferred brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Tech to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal info so you are able to invest in XERS today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to start a new brokerage account.
- Submit your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've finished signing up on the best stock app, you need to deposit funds:
Watch this video walkthrough for more details transferring money into your new investment account.
Step 4: Research Xeris Biopharma Holdings stock
Once you have decided on the best place to buy Xeris Biopharma Holdings stock, it's crucial to evaluate their stock before you buy, so you can understand the risk and upside.
Xeris Biopharma Holdings stock quick numbers
XERS Fundamentals
WallStreetZen was created to help everyday investors do more accurate fundamental analysis quickly.
You can see all of the due diligence checks on XERS's stock page.
Is XERS stock undervalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge XERS's true value.
Using relative valuations ratios:
- XERS could be overvalued based on its P/B ratio of 70.67x, relative to Biotechnology industry P/B ratio of 4.76x
You can do additional valuation analysis on XERS's stock here.
A quick look at XERS Financials
Positive Financial Indicators:
- XERS profit margin has gone up from -27% to 0.2% in the past year.
- There are more short-term assets than short-term liabilities on the XERS balance sheet.
Negative Financial Indicators:
- Total XERS debt is higher than 5 years ago, relative to shareholder equity.
- There are more long-term liabilities than short-term assets on the XERS balance sheet.
- XERS has a relatively high debt to equity ratio of 27.02.
- XERS's operating cash flow of $28.63M allows it to safely service it's debt of $258.10M.
- XERS earnings of $29.64M is not enough to cover its interest payments.
Do Wall Street analysts think it's a good time to buy XERS stock
Out of 4 Wall Street analysts who give recommendations on XERS, the consensus analyst rating on Xeris Biopharma Holdings is a Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are projecting on the Xeris Biopharma Holdings stock forecast page.
XERS Momentum
XERS Performance Metrics
Last year, XERS revenue was $291.85M. In the last 5 year, XERS's revenue has gone up by 70.2% per year. This was faster than the Biotechnology industry average of 28.23%.
Dig into XERS's earnings and revenue performance here.
Are XERS insiders buying or selling the stock?
In the past year, insiders at XERS have sold more shares than they have bought.
Kevin McCulloch, President and Chief Operating Officer of XERS, was the latest XERS insider to buy. They bought $199,976.46 worth of XERS stock on Mar 12, 2026.
Dig into more about who owns XERS shares here.
Does XERS provide a stable income stream?
No, Xeris Biopharma Holdings doesn't provide an income stream by paying out dividends.
What do other investors have to say about XERS?
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your XERS trade
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally sufficient. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a given dollar amount, use a limit order.
Click the Open Trade button and eToro will execute the order.
If you require more help investing in stocks on eToro, watch the helpful video below:
Step 6: Get notifications regarding your XERS investment
Now that you own some XERS shares, you'll want to keep up with your investment.
Make a watchlist to keep track of your XERS stock.
XERS Feed
How to Buy Stock in Xeris Biopharma Holdings
To summarize, here are the 6 steps to buy Xeris Biopharma Holdings stock:
- Choose where to buy Xeris Biopharma Holdings stock
- Create a brokerage account
- Deposit funds into your investment account
- Research Xeris Biopharma Holdings stock
- Place your XERS trade
- Get notifications regarding your XERS investment
If you need a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to monitor your new investment in Xeris Biopharma Holdings, click the button below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.